ArticleEndoscopy international open2026
Diagnostic value of non-magnifying gastroscopy followed by targeted biopsy for detection of early gastric cancer: Multicenter prospective study.
Article in Endoscopy international open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and study aims: Non-magnifying endoscopy remains the most essential tool for detecting early gastric cancer (EGC), but there is still a lack of widely accepted diagnostic methods. We established an optimized EGC detection protocol using non-magnifying gastroscopy-guided targeted biopsy of morphological suspicious lesions and evaluated its effectiveness. Methods: This study included 5738 participants across four medical centers in China. Targeted biopsies were performed on the following suspicious lesions for high-grade neoplasia (HGN) under screening non-magnifying gastroscopy: 1) ulcerative lesions; 2) esophagogastric junction reddish lesions outside the atrophic area; 3) pale or well-demarcated lesions outside the atrophic area, except polypoid lesions smaller than 5 mm; 4) elevated lesions with clear borders or uneven top within the atrophic area; and 5) flat/depressed lesions with irregular borders or uneven surface or ocher color under narrow-band imaging (NBI) within the atrophic area. Sensitivity for detecting gastric HGN and the positive predictive value (PPV) of targeted biopsy were calculated. Results: The targeted biopsy method demonstrated a sensitivity of 90.9% (50/55, 95% confidence interval [CI] 83.1%-98.8%) and a PPV of 5.4% (50/931, 95% CI 3.9%-6.8%) for diagnosing HGN on per-lesion assessment. Lesions that met the suspicious morphological criteria carried a significant risk to be HGNs, even after adjusting for age, sex, and other risk factors associated with gastric cancer (adjusted odds ratio = 42.03, 95% CI 11.14-158.63, Conclusions: Targeted biopsy of suspicious lesions for HGN with non-magnifying gastroscopy can be used as a primary clue for detecting EGC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.